Species distribution and in vitro antifungal susceptibility of oral yeast isolates from Tanzanian HIV-infected patients with primary and recurrent oropharyngeal candidiasis

Table 3 In vitro susceptibility of oral isolates to fluconazole and itraconazole as related to previous antifungal therapy

Antifungal	Previous antifungal (n = 176^a)			No previous antifungal (n = 128^b)			P-value
	S	SDD	R	S	SDD	R
Fluconazole	149 (84.7)	17 (9.7)	10 (5.7)	112 (93.3)	3 (2.5)	5 (4.2)	0.037
Itraconazole	133 (75.6)	22 (12.5)	21 (11.9)	112 (93.3)	4 (3.3)	4 (3.3)	0.002

Data are expressed as number of isolates (percentage).
S – Susceptible, SDD – Susceptible dose dependent, R – resistant.
Interpretive breakpoint criteria of the CLSI (2002): Fluconazole; S (MIC ≤ 8 μg/ml), SDD (MIC 16 – 32 μg/ml), R (MIC 64 μg/ml) and Itraconazole; S (MIC ≤ 0.125 μg/ml), SDD (MIC 0.25 – 0.5 μg/ml), R (MIC ≥ 1).
^aC. albicans (143), C. glabrata (19), C. tropicalis (4), S. cerevisiae (2), C. pintolopesii (1).
^bC. albicans (107), C. glabrata (1), C. tropicalis (4), C. kefyr (3), S. cerevisiae (1), C. dubliniensis (1).

ISSN: 1471-2180